Final Analysis of the Phase 2 ELM-2 Study: Odronextamab in Patients with Relapsed/Refractory (R/R) Diffuse Large B-Cell Lymphoma (DLBCL)

Background Odronextamab is a novel, off-the-shelf, CD20×CD3 bispecific antibody that has demonstrated consistent anti-lymphoma activity and a generally manageable safety profile in heavily pretreated patients (pts) with both R/R follicular lymphoma and R/R DLBCL. Encouraging results have been report...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Blood 2023-11, Vol.142 (Supplement 1), p.436-436
Hauptverfasser:	Ayyappan, Sabarish, Kim, Won Seog, Kim, Tae Min, Walewski, Jan, Cho, Seok-Goo, Jarque, Isidro, Iskierka-Jazdzewska, Elzbieta, Poon, Michelle, Oh, Sung Yong, Inng Lim, Francesca Lorraine Wei, Carpio, Cecilia, Tan, Tran-Der, Gutiérrez, Antonio, Zhang, Huilai, Cao, Junning, Zhang, Mingzhi, Tessoulin, Benoit, Li, Jingjin, Ufkin, Melanie, Shariff, Saleem, Chi, Lei, Chaudhry, Aafia, Mohamed, Hesham, Ambati, Srikanth, Prince, H. Miles
Format:	Artikel
Sprache:	eng
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!